Deutsche Bank (ETR:DBKGn) initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT), assigning a Hold rating to the ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

The most important therapy in Sarepta Therapeutics' portfolio is Elevidys, which last year earned full FDA approval for use in ambulatory Duchenne muscular dystrophy patients. The medicine also ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands ...

Equities researchers at Zacks Research lifted their Q4 2024 earnings estimates for Sarepta Therapeutics in a research note issued to investors on Monday, February 3rd. Zacks Research analyst S.

Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...

ELEVIDYS has been granted orphan drug designation ... So as you said, this study is being run by partner Sarepta. We have a very good collaboration with them and we are excited to see the trial ...

Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling. Elevidys ...